Introduction {#sec1-1}
============

Low cardiac output syndrome (LCOS) remains a dreadful complication occurring in 5%--15% of patients undergoing open-heart surgery.\[[@ref1][@ref2][@ref3][@ref4]\] Systemic hypoperfusion results in multiple organ dysfunction causing prolonged stay in the Intensive Care Unit (ICU) and significant postoperative morbidity and mortality.\[[@ref5]\] Predictors of LCOS have been identified in large cohort studies such as advanced age, impaired systolic and diastolic ventricular function, recent myocardial infarct, renal failure, as well as emergent procedures and prolonged bypass or aortic cross-clamping times.\[[@ref6][@ref7]\]

Nowadays, transesophageal echocardiographic examination (TEE) has been widely adopted in cardiac surgery, and it has largely replaced the pulmonary artery catheter in evaluating cardiac function and in guiding cardiovascular treatments based on a more rational physiological approach.\[[@ref8][@ref9]\] Instead of measuring cardiac output by thermodilution, TEE coupled with standard hemodynamic monitoring provides the unique opportunity to properly diagnose and treat hypovolemia, vasoplegic syndrome, ischemia-related dyskinesia, and myocardial stunning at the bedside.\[[@ref10]\] The term "postcardiotomy ventricular dysfunction" (PCVD) has been coined to define new onset or worsening heart failure that requires the administration of inotropes and/or mechanical support during the weaning period from the cardiopulmonary bypass (CPB).\[[@ref4]\] Causes of PCVD are multifactorial, including surgical tissue trauma, myocardial ischemia-reperfusion injuries, downregulation of beta-adrenergic receptors, coronary embolization (e.g., air, atheroma particle), and activation of inflammatory and coagulation.\[[@ref11]\] The incidence of PCVDs varies from 20% to 60% depending on the definition criteria and the case mix in cardiac surgical patients.\[[@ref12][@ref13]\] Although PCVD can be self-limited -- resolving with transient pharmacological support -- it may also herald a LCOS with its negative prognostic clinical implications.\[[@ref4]\]

Given its high incidence, identification of patient- and procedure-related risk factors of PCVD may represent important targets for improving morbidity and mortality following cardiac surgery. The purpose of the current study was to examine modifiable and nonmodifiable risk factors of PCVD in a cohort of moderate-to-high risk patients undergoing aortic valve replacement (AVR) and/or coronary artery bypass surgery (CABG). This prospective cohort included all patients who were enrolled in a previous randomized control trial that was designed to evaluate the safety and cardioprotective effects of the infusion of glucose-insulin-potassium (GIK) before bypass.

Methods {#sec1-2}
=======

Patient selection and study design {#sec2-1}
----------------------------------

The cohort included patients with severe aortic valve stenosis and/or coronary artery disease who were scheduled for elective AVR and/or CABG at the University Hospital of Geneva. Eligible patients had a Bernstein-Parsonnet score higher than 7. Exclusion criteria consisted of emergent or off-pump surgery, preoperative critical condition, poorly controlled diabetes mellitus, severe liver disease (Child-Pugh C), and dementia or significant cerebrovascular disease.

This single-center trial was approved by the Institutional Review Board at the University Hospital of Geneva (CER: 08-095), it was registered on ClinicalTrials.gov (NCT00788242), and written consent was obtained from each eligible participant.

Prospective data were collected according to the checklist of the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE).

Perioperative management {#sec2-2}
------------------------

The usual medications were continued up to the morning of the procedure, except diuretics, antiplatelets, and angiotensin-converting enzyme inhibitors or angiotensin II antagonists that were interrupted 1 day before. In the operating theater, all patients were equipped with an invasive arterial catheter, a central venous line and a bispectral monitor (BIS) of the electroencephalogram (Aspect Medical Systems A-2000 XP). Anesthesia management consisted of intrathecal morphine (10 mcg/kg), low doses of intravenous sufentanil and an infusion of propofol to target BIS values between 40 and 60. Cardiac preconditioning was also provided with volatile anesthetics (before CPB).

A TEE probe (Matrix Array Probe X7-2t; Philips Medical Systems, Andover, MA, USA) was introduced after anesthesia induction, and images were digitally acquired before and after CPB and stored with the iE33 ultrasound imaging system (Philips Medical Systems, Andover, MA, USA).\[[@ref14]\] Patients were given either the GIK solution (human Actrapid, Novo Nordisk 20 IU and potassium chloride 10 mEq in 50 ml of 40% glucose) or a similar volume of normal saline over 40 min starting after the anesthetic induction.

After full heparinization, normothermic CPB was instituted with a nonpulsatile flow (2.2--2.5 L/min/m^2^) and alpha-stat control for acid--base management. The circuit and the membrane oxygenator were primed with 2 L of clear fluids (1 L Ringer-Acetate and 1 L of hydroxyethyl starch 6% 130/0.4). Mean arterial pressure (MAP) was maintained between 50 and 70 mmHg with vasoactive medications as necessary. During aortic cross-clamping, myocardial protection was achieved by intermittent antegrade infusion of cold blood. Antifibrinolytic therapy with tranexamic acid was administered before CPB (15 mg/kg intravenous over 10 min) and in the CPB priming fluid (10 mg/kg). Packed red blood cells were transfused if a hemoglobin level \<60--65 g/L during CPB or \<80--90 g/L after CPB was achieved; higher transfusion threshold was set in specific groups of patients (e.g., cerebrovascular disease, renal dysfunction, or marginal coronary vascularization).

At the end of the procedure, weaning from CPB was guided by TEE assessment and hemodynamic measurements. After de-airing the cardiac cavities and resumption of mechanical ventilation, the pump flow was gradually reduced and the heart was progressively filled. In addition to fluid loading, electrical atrioventricular pacing, vasopressors, and/or inotropes drugs were given to target the following hemodynamic endpoints: left ventricular (LV) end-diastolic diameter between 2.2 and 2.8 cm/m^2^, MAP between 65 and 100 mmHg, and heart rate between 70 and 100 beats/min. Two cardiothoracic anesthesiologists with extensive experience were directly involved in the perioperative management of each case and adhered to the institutional written guidelines \[[Figure 1](#F1){ref-type="fig"}\].\[[@ref15]\]

![A standardized approach for weaning from bypass](ACA-20-287-g001){#F1}

Study endpoints {#sec2-3}
---------------

In this STROBE compliant descriptive cohort study, we collected all data related to patient demographic and physical status, comorbidities, current medications, anesthetic and surgical management, as well as postoperative cardiac outcome during the primary hospitalization. These data were reported on a case report form and entered in an electronic database.

The diagnostic criteria of PCVD -- the primary study endpoint -- was the need for inotropic support for more than 120 min (dobutamine \>5 mcg/kg/min, epinephrine \>0.05 mcg/kg/min, milrinone \>0.3 mcg/kg/min, and norepinephrine \>0.04 mcg/kg/min) in the presence of impaired ventricular function and a low MAP (\<60 mmHg) despite adequate circulatory filling. Other causes of low arterial pressure such as hypovolemia and vasoplegic syndrome were excluded since these conditions could be corrected with fluid loading and vasopressor therapy, respectively.

As secondary clinical endpoints, we reported in-hospital mortality and the incidence of cardiovascular adverse events (myocardial infarct, atrial fibrillation, LCOS, and stroke), respiratory complications (atelectasis, pneumonia, and mechanical ventilation \>24 h), renal dysfunction (reduction in estimated glomerular filtration \>25%), re-operation, perioperative bleeding (requirement for \>4 packed red blood cell transfusion), and the length of stay in the ICU and until hospital discharge. A modified version of the Dindo-Clavien systemic classification was used to report major adverse events \[[Annex A](#T1){ref-type="table"}\].\[[@ref16]\]

###### 

Modified classification system of postoperative complications\*

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                                                      Cardiovascular                                                                                                             Pulmonary                                                                                                                      Renal                                                    Others
  ------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------ -------------------------------------------------------- ----------------------------
  Grade I: Transient, self-limiting AE                                                                                Nonsustained arrhythmias\                                                                                                  Mild hypoxemia responsive to O~2~ therapy (\<0.3 FiO~2~)                                                                       \<25% decrease in eGFR                                   
                                                                                                                      Hypotension associated with anesthesia induction or mild hypovolemia                                                                                                                                                                                                                                               

  Grade II: AE requiring pharmacologic treatment or minor intervention                                                Arrhythmias requiring pharmacologic treatment\                                                                             Moderate hypoxemia, atelectasis requiring CPAP support                                                                                                                                  Superficial SSI
                                                                                                                      Hypotension associated with mild hypovolemia                                                                                                                                                                                                                                                                       

  Grade IIIa: AE event requiring intervention without sedation/general anesthesia or potentially causing disability   Arrhythmias requiring electrical cardioversion\                                                                            Atelectasis requiring bronchoscopy or intense chest therapy\                                                                   25%-50% decrease in eGFR                                 Deep SSI
                                                                                                                      Hypovolemia requiring aggressive fluid management\                                                                         Moderate-severe Hypoxemia requiring NIV support\                                                                                                                                        
                                                                                                                      Myocardial ischemia\                                                                                                       Pneumonia                                                                                                                                                                               
                                                                                                                      Transient cerebral ischemia                                                                                                                                                                                                                                                                                        

  Grade IIIb: AE requiring intervention under sedation/general anesthesia or causing disability                       Myocardial infarct (mild)\                                                                                                 Severe hypoxemia requiring NIV support (ALI/ARDS, pneumonia, heart failure, muscle failure)                                    \>50% decrease in eGFR                                   Mediastinitis
                                                                                                                      Stroke\                                                                                                                                                                                                                                                                                                            
                                                                                                                      New or worsening heart failure, LCOS requiring pharmacological support (1 drug)                                                                                                                                                                                                                                    

  Grade IVa: Admission in ICU for single organ dysfunction                                                            New or worsening heart failure, LCOS requiring intense pharmacological support (\>2 drugs) and/or mechanical assistance\   Severe hypoxemia requiring intubation and mechanical ventilator support (ALI/ARDS, pneumonia, heart failure, muscle failure)   Renal failure requiring hemodialysis or hemofiltration   
                                                                                                                      Recurrent or sustained arrhythmias\                                                                                                                                                                                                                                                                                
                                                                                                                      Myocardial ischemia/infarct (extensive)                                                                                                                                                                                                                                                                            

  Grade IVb                                                                                                           Cardiac arrest with resuscitation                                                                                                                                                                                                                                                                                  Combined organ dysfunction
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

SSI: Surgical site infection, AE: Adverse event, eGFR: Estimated glomerular filtration rate, CPAP: Continuous positive airway pressure, NIV: Noninvasive ventilation, ALI: Acute lung injury, ARDS: Acute respiratory distress syndrome, LCOS: Low cardiac output syndrome

Statistical analysis {#sec2-4}
--------------------

Perioperative clinical and surgical characteristics as well as postoperative outcome data of patients with and without PCVD were compared with the Chi-square test for categorical variables (expressed in percentage) and the Student\'s *t*-test (normal distribution) or Wilcoxon rank test (non-Gaussian distribution) for continuous variables (all expressed as mean ± standard deviation).

Variables that had a univariate *P* \< 0.15 or those judged to be clinically important were selected for inclusion in a logistic regression model by stepwise forward selection. Only one variable in a set of variables with a correlation coefficient \>0.5 was retained to avoid multicollinearity. Independent predictors of PCVD and factor-adjusted odds ratios (ORs) with 95% confidence interval (CI) were calculated. All analyses were performed using STATA 14 software (Stata Corp., College Station, TX, USA) and statistical significance was specified as a two-tailed Type I error (*P* value) set below the 0.05 level.

Results {#sec1-3}
=======

Over a 5-year period, 295 moderate-to-high risk patients were screened, 243 provided informed consent, 21 were excluded (study staff unavailable, *n* = 7; not meeting selection criteria, *n* = 14), and 222 with completed data were analyzed. In this cohort, 141 patients (64%) received intravenous inotropic drug support and 26 (12%) required assistance with an intra-aortic balloon pump counterpulsation. The criteria of PCVD were met in 63 patients (28.4%). Compared with the group without PCVD, patients with PCVD were significantly older, presented more often signs of heart failure and higher Parsonnet scores, had longer CPB and aortic clamping times, and received less frequently GIK before CPB \[[Table 1](#T2){ref-type="table"}\]. Other clinical and surgical data were similar in the two groups.

###### 

Baseline preoperative and intraoperative characteristics of patients undergoing open cardiac surgery and presenting or not postcardiotomy ventricular dysfunction

  Preoperative                         All (*n*=222)       PCVD (*n*=63)       No PCVD (*n*=159)       *P*
  ------------------------------------ ------------------- ------------------- ----------------------- ------------
  Demographic and clinical data                                                                        
   Age (years)\*                       71.3 (10.7)         74.3 (10.1)         70.1 (10.7)             \<0.001^†^
   Weight (kg)\*                       79.9 (14.7)         78.8 (15.4)         80.4 (14.4)             0.472^†^
   Height (cm)\*                       169.4 (8.6)         170.1 (8.8)         169.1 (8.5)             0.446^†^
   Body mass index\*                   27.9 (5.0)          27.3 (5.5)          28.1 (4.7)              0.281^†^
   Sex (male)                          153 (68.9)          43 (68.3)           110 (69.0)              0.893
   Hypertension                        206 (92.8)          59 (93.7)           147 (92.5)              0.756
   Pulmonary hypertension              22 (9.9)            10 (15.9)           12 (7.6)                0.061
   Diabetes mellitus                   84 (37.8)           25 (39.7)           59 (37.1)               0.721
   Vascular disease                    93 (41.9)           25 (39.7)           68 (42.8)               0.674
   Chronic obstructive lung disease    31 (14.0)           7 (11.1)            24 (15.1)               0.440
   Karnofsky performance status \<50   25 (11.3)           9 (14.3)            16 (10.1)               0.370
   Previous cardiac surgery            15 (6.8)            1 (1.6)             14 (8.8)                0.053
   NYHA class^‡^                       2 (2-3)             2 (2-4)             2 (2-3)                 0.041^§^
   LVEF (%)\*                          45.0 (9.6)          41.9 (11.2)         46.3 (6.9)              0.003^†^
   Parsonnet score\*                   21.2 (8.3)          24.0 (7.6)          20.0 (8.4)              0.001^†^
  Chronic preoperative medications                                                                     
   Beta-blockers                       114 (51.4)          34 (54.0)           80 (80.3)               0.623
   Calcium antagonists                 28 (12.6)           6 (9.5)             22 (13.8)               0.383
   ACEI or angiotensin-II blocker      102 (46.0)          23 (36.5)           79 (49.7)               0.076
   Diuretics                           76 (34.2)           26 (41.3)           50 (31.5)               0.164
   Anti-platelets                      148 (66.7)          38 (60.3)           110 (69.2)              0.207
  Blood parameters                                                                                     
   Hemoglobin (g/dL)\*                 12.2 (2.1)          11.9 (2.2)          12.3 (2.0)              0.211^†^
   Creatinine clearance (mL/min)\*     92.8 (39.9)         84.9 (40.2)         95.9 (39.5)             0.067^†^
                                                                                                       
  **Intraoperative**                   **All (*n*=222)**   **PCVD (*n*=63)**   **No PCVD (*n*=159)**   ***P***
                                                                                                       
  Type of surgery                                                                                      
   Aortic valve replacement            107 (48.2)          30 (47.6)           77 (48.4)               0.913
   Coronary artery bypass graft        81 (36.5)           33 (33.3)           60 (37.7)               0.539
   Combined                            34 (15.3)           12 (19.1)           22 (13.8)               0.331
  Surgical time                                                                                        
   CPB time (min)\*                    108.5 (46.5)        128.2 (55.6)        100.7 (40.1)            \<0.001^†^
   Aortic clamping time (min)\*        77.1 (34.4)         89.1 (38.6)         72.4 (31.6)             0.001^†^
  Fluids                                                                                               
   Crystalloids (mL)\*                 2808 (1090)         3017 (1106)         2725 (1075)             0.072
   Crystalloids (mL/min)\*             12.5 (5.1)          12.2 (5.5)          12.6 (4.9)              0.628
   Colloids (ml)\*                     280 (452)           298 (477)           273 (442)               0.702
   Colloids (mL/min)\*                 1.1 (1.8)           1.1 (2.1)           1.1 (1.8)               0.905
   Blood transfusion                   148 (66.7)          41 (65.1)           107 (67.3)              0.752
   Fresh frozen plasma                 65 (29.3)           22 (34.9)           43 (27.0)               0.245
   Platelets                           36 (16.2)           13 (20.6)           23 (14.5)               0.261
   GIK before CPB                      110 (50.0)          18 (28.6)           92 (57.9)               \<0.001

Data given as *n* (%) unless otherwise indicated. Chi-squared tests were used for statistical tests unless otherwise indicated. \*Data given as mean (SD), ^†^Student's *t*-test, ^‡^Data given as median (range), ^§^Wilcoxon rank-sum test. ACEI: Angiotensin converting enzyme inhibitor, CPB: Cardiopulmonary bypass, PCVD: Postcardiotomy ventricular dysfunction, NYHA: New York Heart Association, GIK: Glucose-insulin-potassium, LVEF: Left ventricular ejection fraction, SD: Standard deviation

Of the 28 preoperative and intraoperative variables subjected to univariate analysis, nine demonstrated a significant association with the occurrence of PCVD: age older than 75 years, low body mass index, low LV ejection fraction (LVEF), elevated Parsonnet score, renal dysfunction, perioperative bleeding, a long bypass time or aortic clamping time, and the administration of GIK \[[Table 2](#T3){ref-type="table"}\]. A significant correlation was found between aortic clamping time and CPB time (*R*^2^ = 0.731) and therefore only aortic clamping time was considered into the logistic regression model. Likewise, the Bernstein-Parsonnet score was not included in the model to avoid multicollinearity.

###### 

Effect of patient characteristics and perioperative management on the occurrence of postcardiotomy ventricular dysfunction

  Preoperative patient characteristics              PCVD              OR           95% CI       *P*          
  ------------------------------------------------- ----------------- ------------ ------------ ------------ ---------
  Age \>75 (years)                                                                                           
   Yes                                              38 (40.4)         56 (59.6)    2.80         1.51-5.19    \<0.001
   No                                               25 (19.5)         103 (80.5)   1.00         Reference    \-
  Body mass index                                                                                            
   \>21-30                                          40 (28.2)         102 (71.8)   1.00         Reference    \-
   \>30                                             18 (25.0)         54 (75.0)    0.85         0.44-1.93    0.623
   ≤21                                              5 (62.5)          3 (37.5)     4.22         0.94-19.12   0.040
  Sex                                                                                                        
   Male                                             43 (28.1)         110 (71.9)   1.00         Reference    \-
   Female                                           20 (29.0)         49 (71.0)    1.04         0.56-1.96    0.893
  High blood pressure                                                                                        
   Yes                                              59 (28.6)         147 (71.4)   1.20         0.37-3.90    0.756
   No                                               4 (25.0)          12 (75.0)    1.00         Reference    \-
  Pulmonary hypertension                                                                                     
   Yes                                              10 (45.5)         12 (54.6)    2.31         0.93-5.71    0.062
   No                                               53 (26.5)         147 (73.5)   1.00         Reference    \-
  Diabetes                                                                                                   
   Yes                                              25 (29.8)         59 (70.2)    1.12         0.61-2.03    0.722
   No                                               38 (27.5)         100 (72.5)   1.00         Reference    \-
  Vascular disease                                                                                           
   Yes                                              25 (26.9)         68 (73.1)    0.88         0.49-1.60    0.675
   No                                               38 (29.5)         91 (70.5)    1.00         Reference    \-
  Chronic obstructive lung disease                                                                           
   Yes                                              7 (22.6)          24 (77.4)    0.70         0.29-1.73    0.441
   No                                               56 (29.3)         135 (70.7)   1.00         Reference    \-
  Karnofsky performance status \<50                                                                          
   Yes                                              9 (36.0)          16 (64.0)    1.49         1.69-3.58    0.371
   No                                               54 (27.4)         143 (72.6)   1.00         Reference    \-
  Parsonnet score \>22                                                                                       
   Yes                                              40 (40.8)         58 (59.2)    3.03         1.62-5.67    \<0.001
   No                                               23 (18.6)         101 (81.5)   1.00         Reference    \-
  LVEF \<40%                                                                                                 
   Yes                                              25 (51.0)         23 (49.0)    3.70         1.85-7.40    \<0.001
   No                                               38 (22.0)         135 (78.0)   1.00         Reference    \-
  NYHA class ≥3^\#^                                                                                          
   Yes                                              22 (36.7)         38 (63.3)    1.71         0.90-3.24    0.096
   No                                               41 (25.3)         121 (74.7)   1.00         Reference    \-
  Anemia (Hb \<100g/l)                                                                                       
   Yes                                              12 (42.9)         16 (57.1)    2.10         0.92-4.78    0.070
   No                                               51 (26.3)         143 (73.7)   1.00         Reference    \-
  Renal insufficiency (eGFR \<60)                                                                            
   Yes                                              18 (41.9)         25 (58.1)    2.14         1.06-4.33    0.029
   No                                               45 (25.1)         134 (74.9)   1.00         Reference    \-
  Chronic preoperative medications                                                                           
   Beta-blockers                                                                                             
    Yes                                             34 (29.8)         80 (70.2)    1.16         0.64-2.08    0.624
    No                                              29 (26.9)         79 (73.2)    1.00         Reference    \-
   Calcium antagonists                                                                                       
    Yes                                             6 (21.4)          22 (78.6)    0.66         0.25-1.71    0.384
    No                                              57 (29.4)         137 (70.6)   1.00         Reference    \-
   ACEI or angiotensin-II blocker                                                                            
    Yes                                             23 (22.6)         79 (77.5)    0.58         0.32-1.07    0.076
    No                                              40 (33.3)         80 (66.7)    1.00         Reference    \-
   Diuretics                                                                                                 
    Yes                                             26 (34.2)         50 (65.8)    1.53         0.83-2.81    0.165
    No                                              37 (25.3)         109 (74.7)   1.00         Reference    \-
   Anti-platelets                                                                                            
    Yes                                             38 (25.7)         110 (74.3)   0.68         0.37-1.25    0.201
    No                                              25 (33.8)         49 (66.2)    1.00         Reference    \-
                                                                                                             
  **Surgical and intraoperative characteristics**   **PCVD**          **OR**       **95% CI**   ***P***      
                                                                                                             
  **Yes, *n* (%)**                                  **No, *n* (%)**                                          
                                                                                                             
  Type of surgery                                                                                            
   CABG                                             21 (25.9)         60 (74.1)    1.00         Reference    \-
   AVR                                              30 (28.0)         77 (72.0)    1.11         0.58-3.13    0.747
   Combined                                         12 (35.3)         22 (64.7)    1.56         0.66-3.69    0.313
  Previous cardiac surgery                                                                                   
   Yes                                              1 (36.0)          14 (64.0)    0.17         0.02-1.33    0.054
   No                                               62 (27.4)         145 (72.6)   1.00         Reference    \-
  Bleeding                                                                                                   
   Yes                                              16 (42.1)         22 (57.9)    2.12         1.02-4.41    0.040
   No                                               47 (25.5)         137 (74.5)   1.00         Reference    \-
  Long aortic clamping time\*                                                                                
   Yes                                              24 (45.3)         29 (54.7)    2.76         1.42-5.36    \<0.001
   No                                               39 (23.1)         130 (76.9)   1.00         Reference    \-
  Long CBP time\*\*                                                                                          
   Yes                                              23 (43.4)         30 (56.6)    2.42         1.26-4.79    0.006
   No                                               40 (23.7)         129 (76.3)   1.00         Reference    \-
  Prebypass GIK                                                                                              
   Yes                                              18 (16.4)         92 (83.6)    0.29         0.15-0.56    \<0.001
   No                                               45 (40.2)         67 (59.8)    1.00         Reference    \-
  Blood transfusion                                                                                          
   Yes                                              41 (27.7)         107 (72.3)   0.91         0.49-1.68    0.753
   No                                               22 (29.7)         52 (70.3)    1.00         Reference    \-
  Fresh frozen plasma                                                                                        
   Yes                                              22 (33.9)         43 (66.2)    1.45         0.77-2.71    0.246
   No                                               41 (26.1)         116 (73.9)   1.00         Reference    \-
  Platelets                                                                                                  
   Yes                                              13 (36.1)         23 (63.9)    1.54         0.72-3.28    0.262
   No                                               50 (26.9)         136 (73.1)   1.00         Reference    \-
  Fluids (\>12.5 mL/min)                                                                                     
   Yes                                              26 (23.4)         85 (76.6)    0.61         0.34-1.11    0.102
   No                                               37 (33.3)         74 (66.7)    1.00         Reference    \-

\*\>75 percentile stratified for surgery: CABG \>80 min, AVR \>96 min; combined \>120 min, \*\*\>75 percentile stratified for surgery: CABG \>120 min, AVR \>127 min; combined \>160 min. ACEI: Angiotensin-converting enzyme inhibitors, eGFR: Estimated glomerular filtration rate, Hb: Hemoglobin, NYHA: New York Heart Association functional classification of heart failure, CABG: Coronary artery bypass graft, AVR: Aortic valve replacement, CPB: Cardiopulmonary bypass, PCVD: Postcardiotomy ventricular dysfunction, OR: Odds ratio, CI: Confidence interval, GIK: Glucose-insulin-potassium, LVEF: Left ventricular ejection fraction

Logistic regression analysis identified five independent predictors of PCVD \[[Table 3](#T4){ref-type="table"}\]: prebypass GIK (OR = 0.14; 95% CI, 0.06--0.33), LVEF \<40% (OR = 6.36; 95% CI, 2.59--15.60), age older than 75 years (OR = 3.35; 95% CI, 1.64--6.81), prolonged clamping time (OR = 3.72; 95% CI, 1.66--8.36), and perioperative bleeding (OR = 2.33; 95% CI, 1.01--5.41). This multivariate model for predicting LV dysfunction was accurate, with an area under the receiver operating characteristic curve of 0.81 and a Hosmer-Lemeshow goodness-of-fit value of 0.91 indicating good model calibration. There was no evidence that additional covariates would improve the model (*P* = 0.539 by the likelihood-ratio test).

###### 

Logistic regression analysis showing the adjusted odds ratios for variables independently associated with the occurrence of postcardiotomy ventricular dysfunction

                                      Adjusted OR   95% CI       *P*^\#^
  ----------------------------------- ------------- ------------ ---------
  GIK                                 0.14          0.06-0.33    \<0.001
  LVEF \<40%                          6.36          2.59-15.60   \<0.001
  Age \>75 (years)                    3.35          1.64-6.81    \<0.001
  Prolonged aortic cross-clamping\*   3.72          1.66-8.36    \<0.001
  Perioperative bleeding              2.33          1.01-5.41    0.048

\*\>75 percentile stratified for surgery: CABG \>80 min, AVR \>96 min; combined \>120 min, ^\#^Wald test. CI: Confidence interval, OR: Odds ratio, CABG: Coronary artery bypass surgery, AVR: Aortic valve replacement, GIK: Glucose-insulin-potassium, LVEF: Left ventricular ejection fraction

Postoperative outcome data are shown in [Table 4](#T5){ref-type="table"}. Compared with patients without PCVD, those experiencing PCVD presented higher in-hospital mortality (12.7% vs. 0.6%, *P* \< 0.001) with increased incidences of cardiovascular and respiratory complications as well as renal dysfunction. Noteworthy, among patients with PCVD, myocardial infarct developed more frequently (19 \[30.2%\] vs. 12 \[7.6%\] in patients without PCVD) as well as a LCOS (24 \[38.1%\] vs. 11 \[6.9%\]). Furthermore, the need for prolonged mechanical ventilation and the ICU and hospital length of stay were significantly higher in patients with PCVD.

###### 

Outcome of patients with and without postcardiotomy ventricular dysfunction

  Outcome                         All (*n*=222)   PCVD (*n*=63)    No PCVD (*n*=159)   *P*
  ------------------------------- --------------- ---------------- ------------------- ------------
  Mortality                       9 (4.5)         8 (12.7)         1 (0.6)             \<0.001°
   AVR                            2 (1.9)         2 (6.7)          0                   0.077°
   CABG                           3 (3.7)         3 (14.3)         0                   0.016°
   Combined surgery               4 (11.8)        3 (25.0)         1 (4.6)             0.115°
  Cardiovascular complications                                                         
   Atrial fibrillation            98 (44.1)       34 (54.0)        64 (40.3)           0.064
   Low cardiac output syndrome    35 (15.8)       24 (38.1)        11 (6.9)            \<0.001
   Myocardial infarct             31 (14.0)       19 (30.2)        12 (7.6)            \<0.001
   Stroke                         10 (4.5)        2 (3.2)          8 (5.0)             0.729
   Troponin I (day 1) (µg/L)^‡^   3.4 (1.8-6.4)   5.3 (3.0-14.3)   3.1 (1.6-5.8)       \<0.001^§^
  Respiratory complications                                                            
   Atelectasis                    76 (34.2)       31 (49.2)        45 (28.3)           \<0.001
   Pneumonia                      20 (9.0)        13 (20.6)        7 (4.4)             \<0.001
   Ventilation \>24 h             95 (42.8)       44 (69.8)        51 (32.1)           \<0.001
  Renal dysfunction                                                                    
   Reduction in GFR \>25%         44 (19.8)       20 (31.8)        24 (15.1)           0.005
  Surgical complications                                                               
   Bleeding                       38 (17.1)       16 (25.4)        22 (13.8)           0.039
   Need for redo surgery          17 (7.7)        7 (6.3)          10 (11.1)           0.771
   Length of stay (days)                                                               
   ICU^‡^                         3 (2-5)         5 (3-11)         3 (2-4)             \<0.001^§^
   Hospital^‡^                    15 (12-21)      20 (15-27)       14 (11-17)          \<0.001^§^

Data given as *n* (%) unless otherwise indicated. Chi-squared tests were used for statistical tests unless otherwise indicated. ^‡^Data given as median (range), ^§^Wilcoxon rank sum test, °Fisher's exact test. PCVD: Postcardiotomy ventricular dysfunction, CABG: Coronary artery bypass surgery, AVR: Aortic valve replacement, GFR: Glomerular filtration rate, ICU: Intensive Care Unit

Discussion {#sec1-4}
==========

In this cohort including moderate-to-high-risk patients scheduled for open heart surgery, 28% of them experienced PCVD and these patients had a prolonged stay in the ICU owing to more frequent cardiopulmonary complications and renal dysfunction compared with patients without PCVD. Advanced age, preoperative low LVEF, perioperative bleeding, and prolonged aortic clamping time were all identified as independent risk factors of PCVD whereas the administration of GIK before bypass was associated with myocardial protection.

The elevated risk profile of this cohort was mainly related to advanced age (63% ≥70 years) and a high prevalence of some comorbidities (hypertension in 93% of patients, LVEF \<50% in 65%, diabetes mellitus in 28%, and chronic obstructive lung disease in 14%). According to a mean Parsonnet score of 21, the overall predicted mortality was 5.5%\[[@ref17]\] and the lower observed mortality (4.0%) could partly be attributed to the perioperative protocol-driven approach where the anesthetic and surgical techniques were standardized and a goal-directed protocol based on TEE and hemodynamic monitoring was applied to separate patients from CPB.

In the current trial, the main study endpoint --PCVD -- was clearly defined as the need for prolonged pharmacological inotropic support and was helpful to identify patients at risk for adverse postoperative clinical outcome. Weaning the patient from the CPB remains a critical phase where both the cardiac surgeon and the anesthesiologist share important information regarding the completeness of surgery and postischemic functional recovery of the heart. Within a short time, important decisions are taken regarding additional surgical interventions in case of ongoing myocardial ischemia, paravalvular regurgitation, or valve prosthesis mismatch.\[[@ref18]\] Likewise, cardiovascular drugs are selectively prescribed and titrated to support the failing heart and to correct the vasoplegic syndrome that often occurs after myocardial ischemia-reperfusion.\[[@ref10]\]

Although PCVD most often resolved within the first hours after surgery, in 30% of our surgical cases, PCVD forecasted the development of LCOS and it was associated with myocardial infarction and/or ischemia-reperfusion injuries as evidence by a larger release of cardiac troponin. The consequent mismatch between oxygen supply and metabolic requirements was also manifested by decreased glomerular filtration rate and impaired respiratory muscle function along with a prolonged need for mechanical ventilation and a higher propensity for pulmonary complications. Moreover, the perioperative use of inotropes could further contribute to worsen postoperative clinical outcome as reported in several large cohort studies where inotrope therapy has been identified as a risk factor of postoperative mortality and cardiovascular complications.\[[@ref19][@ref20][@ref21]\] Indeed, catecholamines may transiently enhance postischemic functional recovery and accelerate weaning from bypass; however, by promoting insulin resistance and fatty acid oxidation (instead of glucose utilization), the administration of catecholamines increases myocardial oxygen consumption and deplete energetic substrates within the cardiomyocytes.\[[@ref22]\] Consequently, short-term hemodynamic improvement can be outweighed by adverse events related to arrhythmias, hyperglycemia, lactic acidosis, and beta-adrenergic receptor desensitization.

The risk factors for PCVD in the current study were similar to those reported for LCOS in previous studies,\[[@ref3][@ref6][@ref23]\] and this emphasizes the clinical and pathophysiological continuum between these two entities. Preoperative risks factors such as advanced age and low LVEF are not amenable to optimization therapies. Experimental evidence supports that the senescent hearts are more vulnerable to ischemic insults while being also more refractory to protective interventions.\[[@ref24]\] Likewise, in patients with low LVEF, the wide range in myocardial viability due to remodeling and fibrotic changes results in a greater propensity to ischemia-reperfusion injuries.\[[@ref25]\] Importantly, these "non-modifiable" factors are also included in the popular risk scoring systems (e.g., EuroScore, Parsonnet, Society of Thoracic Surgery) as risk factors to predict mortality after cardiac surgery and therefore might be useful to select the surgical candidates and to rationalize resources utilization in the hospital.\[[@ref17][@ref26]\]

It is worth mentioning that these current risk classification systems do not consider the intraoperative time course which can be a decisive factor for the postoperative patient\'s clinical outcome.\[[@ref27]\] In the present trial, we found that the duration of aortic cross-clamping and perioperative bleeding were predictors of PCVD. Interestingly, these intraoperative factors can be modified by implementing dedicated protocols and by improving the expertise, the skills and experience of the heart team. Aortic cross-clamping time reflects ischemic injury and despite modern myocardial protection techniques, it remains a prominent mechanism leading to LCOS regardless of the preoperative LVEF.\[[@ref28][@ref29][@ref30]\] Noteworthy, prolonged aortic clamping times and perioperative bleeding may also denote technical difficulties in executing the planned operation because of unfavorable anatomy or intraoperative complications. Besides perioperative bleeding, preoperative anemia and low hematocrit during CPB have also been identified as modifiable risk factors of postoperative mortality, renal failure and cardiovascular morbidity.\[[@ref31]\]

These intraoperative factors are closely related since both CPB and myocardial ischemia-reperfusion trigger a systemic inflammatory response manifested by a hyperdynamic circulatory state, alteration in platelet function and coagulation factors, activation of leucocytes and endothelial cells, as well as the release of cytokines and oxygen free radicals.\[[@ref11]\] Therefore, prolonged duration of CPB and aortic cross-clamping has been associated not only with PCVD but also with more frequent pulmonary complications, larger requirement for transfusion, and renal impairment.\[[@ref28]\] Besides standard anterograde blood cardioplegia, the implementation of GIK before CPB was associated with a marked attenuation of the PCVD, supporting the growing body of scientific knowledge on GIK-induced myocardial protection.\[[@ref32][@ref33]\] The enhanced postischemic ventricular function could be attributed to the higher glycogen stores as the energetic pathway can be switched from fatty acids to glucose oxidation when the GIK metabolic cocktail is given before ischemia.\[[@ref34][@ref35]\]

There are some limitations in our study. First, our study remains retrospective despite the fact that all data were prospectively collected, and as such, we can only report on associations rather than causality between the PCVD and the reported risk factors. Second, potential risk factors such as preoperative renal dysfunction, frailty or functional dependency, diabetes, vascular disease, or prior cardiac surgery could not be analyzed given the relatively small sample size of the study population and the low prevalence of some comorbidities. Likewise, patients with severe organ failure were excluded and exploring the impact of critical concomitant illnesses would deserve larger cohorts with a wider range of pathologies. Finally, the limitations related to this single-center study, its retrospective design, and the small sample preclude generalizability of our results.

Conclusions {#sec1-5}
===========

Our data indicate that age, duration of aortic cross-clamping, and preexisting LV systolic dysfunction are independent risk factors for early PCVD whereas the administration of GIK is association with a lower incidence of PCVD in moderate-to-high risk patients undergoing AVR or coronary artery bypass graft surgery. These data strengthen the need for randomized controlled trials testing perioperative management strategies aimed to target modifiable risk factors in patients undergoing cardiac surgery.
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